Not logged in Side effect management and procedural best practices with indwelling intravesical drug-releasing systems in the treatment of bladder cancer: recommendations from expert panels Pradere, Benjamin; Schuit, Maarten; Guerrero-Ramos, Felix; Shariat, Shahrokh F.; Kitamura, Hiroshi; Jacob, Joseph M.; Bao, Yige; Heesakkers, John; Peters, Kenneth M.; Cahn, David J.; De Troyer, Bart; Herrera Imbroda, Bernardo; Morris, David S.; Pieczonka, Christopher M.; Wei, Qiang; Bhanvadia, Sumeet; Somer, Robert; Jessner, Wolfgang; Triantos, Spyros; Sanchez de Llano, Cristina; Maffeo, John C.; Sweiti, Hussein; Psutka, Sarah P. Share Save
Prognostic Impact of Oncogenic Fibroblast Growth Factor Receptor Alterations in Patients With Advanced Solid Tumors in a Real-World Setting Demirdjian, Levon; Triantos, Spyros; Standish, Kristopher; Thomas, Shibu; Xia, Qi; Zhang, Jiarui; Greshock, Joel; Paone, Julie; Sheridan, Paige; Pant, Shubham; Massard, Christophe; Reardon, David A.; Loriot, Yohann; Schuler, Martin; Sweiti, Hussein Share Save
Association of PD-L1 expression with clinical response to TAR-200 in the phase IIb SunRISe-1 trial Xylinas, E.; Pieczonka, C.; Jacob, J. M.; Necchi, A.; Daneshmand, S.; Simone, G.; Decaestecker, K.; Kulkarni, G.; Boegemann, M.; Guerrero-Ramos, F.; Callaway, J.; Beeharry, N.; Zhang, J.; Hampras, S.; Sweiti, H.; Stromberg, K.; Martin, J.; Shukla, A.; Raciti, P.; van der Heijden, M. S. Share Save
TAR-200+/- cetrelimab (CET) and CET alone in patients (pts) with bacillus Calmette- Guerin-unresponsive (BCG UR) high-risk non-muscle-invasive bladder cancer (HR NMIBC): Updated results from SunRISe-1 (SR-1) van der Heijden, M. S.; Simone, G.; Boegemann, M.; Xylinas, E.; Roumiguie, M.; Guerrero-Ramos, F.; Necchi, A.; Daneshmand, S.; Van Praet, C.; Spiegelhalder, P.; Decaestecker, K.; Arentsen, H.; Zainfeld, D.; Hampras, S.; Cutie, C. J.; Sweiti, H.; Stromberg, K.; Martin, J.; Shukla, A.; Jacob, J. M. Share Save
TAR-200 plus cetrelimab (CET) or CET alone as neoadjuvant therapy in patients (pts) with muscle-invasive bladder cancer (MIBC) who are ineligible for or refuse neoadjuvant cisplatin-based chemotherapy (NAC): Interim analysis of SunRISe-4 (SR-4) Necchi, A.; Guerrero-Ramos, F.; Crispen, P. L.; Imbroda, B. Herrera; Garje, R.; Powles, T. B.; Peyton, C. C.; Pradere, B.; Ku, J. H.; Shore, N. D.; Boegemann, M.; Preston, M. A.; Xylinas, E.; Gong, C.; Najmi, S.; Hasan, M.; Stitou, H.; Bhanvadia, S.; Sweiti, H.; Psutka, S. P. Share Save
Erdafitinib in Asian patients with advanced solid tumors: an open-label, single-arm, phase IIa trial Park, Joon Oh; Feng, Yin-Hsun; Su, Wu-Chou; Oh, Do-Youn; Keam, Bhumsuk; Shen, Lin; Kim, Sang-We; Liu, Xiufeng; Liao, Huimin; Qing, Min; Zhang, Chong; Qian, Jiaqi; Tang, Xiaodan; Li, Peng; Triantos, Spyros; Sweiti, Hussein Share Save
Fibroblast growth factor receptor (FGFR) co-alteration (co-alt) landscape and its impact on erdafitinib (erda) response in the phase II open-label, single-arm RAGNAR trial Loriot, Y.; Pant, S.; Witt, O.; Reardon, D. A.; Doi, T.; Qin, S.; Tabernero, J.; Iyer, G.; Massard, C.; Arnold, D.; Lugowska, I.; Carranza, O.; Gutierrez, M.; Winter, H.; Sweiti, H.; Thomas, S.; Gormley, M.; Zhang, J.; Triantos, S.; Schuler, M. H. H. Share Save
Efficacy and safety of erdafitinib in adults with pancreatic cancer and prespecified fibroblast growth factor receptor alterations (FGFRalt) in the phase II open-label: Single-arm RAGNAR trial Pant, S.; Arnold, D.; Tabernero, J.; Loriot, Y.; Folprecht, G.; Haag, G. M.; Palmer, D.; Prenen, H.; Coward, J.; Lugowska, I.; Goeminne, J-C.; Cervantes, A.; Gutierrez, M.; Sweiti, H.; Hammond, C.; Najmi, S.; Thomas, S.; Triantos, S.; Crow, L.; Schuler, M. H. H. Share Save
SunRISe-3: TAR-200 plus cetrelimab (CET) or TAR-200 versus intravesical bacillus Calmette-Guerin (BCG) in patients (pts) with BCG-naive high-risk non-muscle-invasive bladder cancer (HR NMIBC) Necchi, A.; Catto, J. W. F.; Powles, T. B.; Guerrero-Ramos, F.; Simone, G.; Shore, N. D.; Salinas, J.; Merseburger, A. S.; Roumiguie, M.; Kitamura, H.; Morris, D.; Wei, Q.; Korkes, F.; Hasan, M.; Jin, S.; Maffeo, J.; Hammond, C.; Sweiti, H.; Somer, R.; Chang, S. S. Share Save
Phase II, open-label study of erdafitinib in adult and adolescent patients (pts) with advanced solid tumours harboring fibroblast growth factor receptor (FGFR) gene alterations Schuler, M.; Tabernero, J.; Massard, C.; Iyer, G. Vasudeva; Witt, O.; Doi, T.; Qin, S.; Lu-Emerson, C.; Hargrave, D.; Garcia-Corbacho, J.; Little, S.; Xia, Q.; Santiago-Walker, A.; Moy, C. H.; Hammond, C.; Lau, Y. Y.; Sweiti, H.; Pant, S. Share Save
Share Save
.png){kind=icon}
.png){kind=icon}
Not logged in.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
